SCHEMBL4305307

SCHEMBL4305307

CCN(CC)CC(=O)Nc1ccc2c(c1)C(=O)c1cc(NC(=O)CN(CC)CC)ccc1C2=O

nearest known ligand 0.74

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TERT O14746 13/20 0.74
ALDH1A1 P00352 2/20 0.64
MEN1 O00255 1/20 0.64
NPC1 O15118 1/20 0.64
CYP1A2 P05177 1/20 0.64
POLB P06746 1/20 0.64
CYP3A4 P08684 1/20 0.64
CYP2D6 P10635 1/20 0.64
MAPT P10636 1/20 0.64
CYP2C9 P11712 1/20 0.64
CYP2C19 P33261 1/20 0.64
RAB9A P51151 1/20 0.64
KMT2A Q03164 1/20 0.64
SMN1; SMN2 Q16637 1/20 0.64
GAA P10253 1/20 0.57
PTPRC P08575 1/20 0.56
CASP3 P42574 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9630800 1.00 TERT (0.74) TERTALDH1A1MEN1NPC1CYP1A2
SCHEMBL4303627 0.85 TERT (1.00) TERTALDH1A1MEN1NPC1CYP1A2
SCHEMBL9630529 0.85 TERT (1.00) TERTALDH1A1MEN1NPC1CYP1A2
SCHEMBL4291524 0.84 TERT (0.73) TERTALDH1A1MEN1NPC1CYP1A2
SCHEMBL8705374 0.84 TERT (0.60) TERTALDH1A1MEN1NPC1CYP1A2
SCHEMBL4299908 0.82 ALDH1A1 (0.90) TERTALDH1A1MEN1NPC1CYP1A2
SCHEMBL8701369 0.81 TERT (0.85) TERTALDH1A1MEN1NPC1CYP1A2
SCHEMBL4298269 0.80 PTPRC (0.83) TERTALDH1A1MEN1NPC1CYP1A2
SCHEMBL8700770 0.78 TERT (0.82) TERTALDH1A1MEN1NPC1CYP1A2
SCHEMBL2096053 0.78 POLB (0.67) ALDH1A1MEN1NPC1CYP1A2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090253709-A1 SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES NATIONAL DEFENSE MEDICAL CENTER (TW) 2009-10-08 US disclosed
US-20090253709-A1 SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES NATIONAL DEFENSE MEDICAL CENTER (TW) 2009-10-08 US disclosed
US-20090253709-A1 SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES NATIONAL DEFENSE MEDICAL CENTER (TW) 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253709-A1 SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES TERT, NAT10, POT1 TERT 1/4885ALDH1A1 481/4885MEN1 148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.